Sign in

    Yun Zhong • Wedbush Securities

    Yun Zhong's questions to Ascendis Pharma A/S (ASND) leadership

    Yun Zhong's questions to Ascendis Pharma A/S (ASND) leadership • Q2 2025

    Question

    Yun Zhong from Wedbush Securities asked about the potential launch timing for TransCon CNP following approval and whether a monotherapy arm is still being considered for the hypochondroplasia trial.

    Answer

    President & CEO Jan Møller Mikkelsen stated that launch plans for TransCon CNP would be detailed on a call following regulatory approval. For hypochondroplasia, he reiterated the belief that combination therapy is the most robust treatment for the heterogeneous patient population, but did not rule out including a monotherapy arm in the trial design pending further regulatory discussions.

    Ask Fintool Equity Research AI

    Yun Zhong's questions to MannKind Corp (MNKD) leadership

    Yun Zhong's questions to MannKind Corp (MNKD) leadership • Q2 2025

    Question

    Yun Zhong of Wedbush Securities sought confirmation that the Phase 2 nintedanib trial is not powered for efficacy, asked if the goal is to select one dosing regimen for Phase 3, and inquired about the conditions for drawing additional capital from the Blackstone loan agreement.

    Answer

    CEO Michael Castagna confirmed the Phase 2 trial is not powered for efficacy but is designed to inform the Phase 3 trial, with the goal of selecting a single dosing regimen. CFO Chris Prentiss explained that the initial $125 million of the Blackstone facility is committed and can be drawn at the company's discretion without being tied to specific clinical or sales milestones, as it is intended for general growth initiatives.

    Ask Fintool Equity Research AI

    Yun Zhong's questions to MannKind Corp (MNKD) leadership • Q1 2025

    Question

    Yun Zhong of Wedbush Securities asked to what the strong NRx growth for Afrezza could be attributed and whether the launch strategy for the pediatric indication would mirror the adult strategy.

    Answer

    Executive Michael Castagna attributed the NRx growth to a combination of new INHALE-3 data and strong sales force execution. He stated the pediatric launch strategy will be 'very different' from the adult launch, focusing on children's hospitals and academic centers with a comprehensive plan to be shared later.

    Ask Fintool Equity Research AI

    Yun Zhong's questions to MannKind Corp (MNKD) leadership • Q4 2024

    Question

    Yun Zhong of Wedbush Securities inquired about feedback from adult subjects in the INHALE-3 study and details of the upcoming interim analysis for the clofazimine trial (MNKD-101), including potential study size adjustments.

    Answer

    Executive Michael Castagna reported that about 50% of patients in the INHALE-3 study opted to remain on Afrezza, with outcomes often linked to physician experience. For MNKD-101, he explained the interim analysis will occur after 100 patients reach their endpoint, and enrollment will continue during the analysis to preemptively meet any potential increase in trial size, which could go from 180 up to 300 patients.

    Ask Fintool Equity Research AI

    Yun Zhong's questions to WAVE Life Sciences Ltd (WVE) leadership

    Yun Zhong's questions to WAVE Life Sciences Ltd (WVE) leadership • Q2 2025

    Question

    Yun Zhong of Wedbush Securities questioned what Wave considers a desirable Inhibin E knockdown level for WVE-007 and if dose escalation would continue past cohort three. He also asked if recent FDA updates would affect the company's strategy for its DMD program.

    Answer

    President & CEO Paul Bolno responded that the 240 mg dose (cohort two) was modeled to replicate effects seen in their DIO mouse model and that the company is not stopping there, with the 400 mg cohort already dosing and the potential to go higher if needed. Regarding the DMD program, Bolno noted their program is with CDER and that while they are monitoring the situation at the FDA, there is nothing to suggest their current plan for an NDA submission in 2026 is changing.

    Ask Fintool Equity Research AI